Pathway deep in the brain makes it resilient after injury

SAN FRANCISCO, CA—For days, and even years, after someone suffers a stroke or traumatic brain injury, they have an increased risk of developing epilepsy. Now, researchers at Gladstone Institutes discovered that star-shaped cells called astrocytes in the thalamus play a key role in making mice with brain injuries susceptible to seizures.

The team also analyzed human post-mortem brain tissue and showed that the same cells identified in mice might be altered in the thalamus of people affected by brain injury and stroke. The findings, published in the journal Science Translational Medicine, suggest that targeting a protein in these cells could prevent the long-term damage that follows brain injury.

“In the aftermath of brain injuries, the thalamus has been relatively understudied compared to other brain regions,” says Jeanne Paz, PhD, an associate investigator at Gladstone and senior author of the new study. “I’m hoping this is just the beginning of many new lines of research about how important this region is in determining how we can help the brain be resilient to consequences of injuries.”

A Cascade of Inflammation Deep in the Brain

At the time of a stroke or traumatic brain injury, many cells at the site of the injury die almost immediately. Inflammatory cells and molecules begin to gather, cleaning up the dead cells and molecular debris. In the thalamus, an area deep in the center of the brain that may be far from the site of injury, cells called astrocytes become activated, leading to a cascade of inflammatory changes.

Previous studies from the team have shown, in rodent models, that activation of astrocytes in the thalamus is a common consequence of brain injury. However, astrocytes also play key roles that support neurons, including controlling their connections and providing them with nutrients.

In this study, the scientists wanted to determine whether the activation of astrocytes in the thalamus helps the brain recover, leads to additional damage, or has both positive and negative effects.

“Astrocytes are so important to the brain that you can’t just get rid of them to treat disease,” says Frances Cho, a graduate student at Gladstone and UC San Francisco (UCSF), and the first author of the new study. “We needed to determine whether we could separate the damaging actions of activated astrocytes from their protective actions.”

Focus on the Thalamus

Paz, Cho, and their collaborators hypothesized that activated thalamic astrocytes might play a role in some of the longer-term symptoms of brain injury—including an increased risk of seizures and sleep problems. So, rather than study mice with brain injuries, the team initially tested the consequences of activating thalamic astrocytes in otherwise healthy animals. They found that just activating thalamic astrocytes was enough to cause altered patterns of brain activity similar to those seen after injury, and made the mice susceptible to seizures.

When the researchers then analyzed the molecular properties of the activated astrocytes, in collaboration with the team of Anna Molofsky, MD, PhD, at UCSF, they discovered that these cells lost a protein called GAT3, which is responsible for regulating the levels of a specific inhibitory neurotransmitter molecule. As a result, the neighboring neurons were exposed to too much of the neurotransmitter, which resulted in neuronal hyperexcitability and susceptibility to seizures.

“We wondered, if the loss of GAT3 in thalamic astrocytes caused neuronal dysfunction, could boosting the level of this protein solve the problem and restore the neurons’ function?” says Paz, who is also an associate professor at UCSF.

To answer this question, the team collaborated with Baljit S. Khakh, PhD, and his group at UCLA who had developed a tool to increase GAT3 specifically in astrocytes. Remarkably, increasing levels of GAT3 specifically in thalamic astrocytes was enough to prevent neuronal hyperexcitability and increased seizure risk caused by activated astrocytes.

The team next tested whether the results held true in mice with brain injuries. Increasing levels of GAT3 in the thalamic astrocytes of these mice also reduced the risk of seizure and the rate of mortality.

“These activated astrocytes are quite different in many ways than astrocytes that are not activated, so it was surprising we could pinpoint a single molecular change that we could target to prevent the consequences of brain injury,” says Cho.

A Potential Therapeutic

Samples of human thalamus are rarely collected during post-mortem brain biopsies. But, in collaboration with Eleonora Aronica, MD, PhD, and her group at the University of Amsterdam, the researchers were able to obtain a small number of post-mortem thalamus samples—three from individuals with no known brain injuries, three from people who had had a stroke, and four from people with traumatic brain injury.

“The post-mortem brains with stroke and traumatic brain injury seemed to have lower levels of GAT3 in their thalamic astrocytes, just as we had seen in the mouse model,” says Cho. “We hope that with increased attention to the thalamus, it will become more routine to collect thalamus samples from post-mortem biopsies in the future.”

The researchers hope to continue collecting longer-term data on both mice and humans to study the time course of astrocyte activation in the thalamus after brain injury.

“Since these changes to the thalamus occur after the initial brain injury, there is a window of time in which clinicians might be able to intervene to stop or reverse them—and prevent the increased risk of developing epilepsy,” says Paz.

###

About the Research Project

The paper “Enhancing GAT-3 in thalamic astrocytes promotes resilience to brain injury” was published in the journal Science Translational Medicine on July 6, 2022.

Other authors are Yuliya Voskobiynyk, Allison Morningstar, Bryan Higashikubo, and Agnieszka Ciesielska of Gladstone; Ilia Vainchtein and Francisco Aparicio of UCSF; Diede Broekaart, Jasper Anink, Erwin van Vliet and Eleonora Aronica of University of Amsterdam; and Xinzhu Yu of UCLA.

The work was supported by funding from the National Institute of Neurological Disorders and Stroke (F31 NS111819, R01 NS096369, R01 R01NS121287, R00 NS078118, R35 NS111583), the National Institute of Mental Health (DP1 MH104069, DP2 MH116507, R01 MH119349), the National Cancer Institute (P30 CA082103), the National Science Foundation (1144247), a UCSF Discovery Fellowship, the Department of Defense (EP150038, EP190020), a Gladstone Institutes Animal Facility grant (RR18928), Pew Charitable Trusts, an EU Seventh Framework Programme EPITARGET grant (602102), an EU Horizon 2020 Research and Innovation Programme Marie Sklodowska-Curie grant (722053), and the Dutch Epilepsy Foundation (project 16-05).

About Gladstone Institutes

To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impact—unsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with the University of California, San Francisco.

---

---